Breast Biopsy Market Overview
The Breast Biopsy Market was valued at USD 0.71 billion in 2023. The industry is projected to grow from USD 0.76 billion in 2024 to USD 1.36 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4% during the forecast period (2024 - 2032). The increase in prevalence of breast cancer and rising healthcare expenditure are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Breast Biopsy Market Trends
Increase in the prevalence of Breast Cancer
The rising incidence of breast cancer is a significant factor in the market's expansion. The prevalence of breast cancer is significantly rising, raising awareness among people globally to get screened and diagnosed. In order to reduce the occurrence of breast cancer in the population, it is necessary to collect a variety of cumulative data, raise awareness, set up facilities, and treat these patients after a thorough analysis. The two main guidance systems for the accurate detection of breast cancer are mammograms and ultrasounds. Using a variety of modalities, including ultrasound, mammography, and MRI, breast cancer screening helps medical practitioners find breast cancer in a patient. These specialists do breast biopsies for the early detection and diagnosis of breast cancer, assisting patients in receiving the proper care in the event of positive results. The demand for breast biopsy procedures is being driven by the rise in breast cancer incidence among people globally. Thus, it is anticipated that this will accelerate market growth.
Breast Biopsy Market Segment Insights
Breast Biopsy Product Type Insight
The Breast Biopsy Market is segmented, based on product type, into, Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, and Others.
The biopsy needles held the largest share in the market over the forecast period. Breast biopsies fall under the category of needle biopsy, which involves removing a small sample of tissue from the breast using a needle. Setting the lesion and then performing an unguided needle biopsy are the procedures used to perform biopsies on visible lesions. Nevertheless, mammography or ultrasound image guiding type is used if the lesion cannot be felt. Due to the larger core needle's tendency to remove enough tissue to allow the pathologist to evaluate anomalous cells with respect to the adjacent small specimen of breast tissue collected for examination purposes, needle biopsy typically enables a more accurate evaluation of a breast mass than fine-needle aspiration.
The biopsy tables category held a substantial share in the market. Breast tissue biopsies are carried out on specialised medical tables known as breast biopsy tables. A small sample of breast tissue is removed during a biopsy in order to be viewed under a microscope. The comfort and safety of the patient as well as the convenience of use for the medical practitioner conducting the biopsy are frequently taken into consideration while designing the many types of breast biopsy tables that are available.
The biopsy wires category is anticipated to grow at a significant rate over the forecast period. Breast biopsy wires are flimsy, thin wires that help a surgeon pinpoint a lesion or other abnormality in the breast during a surgical biopsy. Before the biopsy operation, they are normally introduced into the breast tissue using a tiny needle. Breast irregularity or lesion that must be biopsied is precisely where the breast biopsy wires are intended to direct the surgeon. The wire is placed inside the breast tissue, where it stays until the procedure. The wire serves as a guide for the surgeon during surgery to aid in locating and removing the aberrant tissue.
The guidance systems category is expected to grow at the lucrative rate over the forecast period. Specialized medical equipment known as breast biopsy guidance systems are used to help direct the biopsy needle to the exact spot of a breast abnormality or lesion. In minimally invasive biopsy methods like stereotactic, ultrasound-guided, or MRI-guided biopsies, these systems are frequently employed. Breast abnormality or lesion location is made easier with the aid of breast biopsy guiding systems, which can be used with a variety of imaging techniques like mammography, ultrasound, or MRI. Even if the abnormal tissue is small or difficult to notice on imaging, these technologies are incredibly accurate and can direct the biopsy needle to the exact location of the abnormal tissue.
Figure 2: BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Breast Biopsy Technique Insights
The Breast Biopsy Market is segmented, based on technique type, into, Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy.
The fine needle aspiration biopsy category is anticipated to grow at a significant rate because of an increase in demand for minimally invasive procedures, primarily. This expansion is also consistent with its broad application in the market for fine needle aspiration breast biopsies. The products sector appears to have experienced the majority of improvements and breakthroughs. For instance, the Stryker PreciseCore needle makes it possible to acquire samples more precisely and with significantly lower risks of causing tissue injury. Furthermore, a significant growth rate is projected for the guiding systems product segment during the forecasted year.
reast Biopsy Guidance Technique Insights
The Breast Biopsy Market is segmented, based on guidance technique, into, Ultrasound-Guided Biopsy, Mammography Guided Magnetic Resonance, CT Guided Biopsy, Other Image-Guided Breast Biopsy (PET and Thermography.
Throughout the forecast period, the ultrasound sector in the global market for breast biopsies is anticipated to develop at the quickest rate. It is the fastest method of them all, and it is fueling the ultrasound-guided breast biopsy market. Moreover, it requires less exposure to ionizing radiation than the standard mammography-guided stereotactic biopsy approach. These are the driving forces behind the expansion of the ultrasound-guided breast biopsy market.
The highest revenue portion came from the mammography-guided magnetic resonance segment. The ability of mammography-guided magnetic resonance to identify early breast cancer in people who are asymptomatic is a critical element in driving this segment's high demand. The success of a cancer diagnosis is greatly influenced by early discovery of the disease. Furthermore, when compared to conventional film mammograms, computer-assisted digital mammograms considerably reduce the amount of radiation that cancer patients are exposed to, saving the patient from potentially toxic side effects.
The CT-guided biopsy held a substantial share in the market. A tissue sample from a breast region that appears suspicious and that has been identified on a CT scan can be obtained via a minimally invasive medical procedure called a CT-guided breast biopsy. In order to retrieve a small sample of breast tissue for microscopic analysis, a biopsy needle is inserted into the breast tissue under the guidance of CT imaging equipment.
Breast Biopsy End-Users Insights
The Breast Biopsy Market is segmented, based on End User, into, Hospitals and Clinics, Diagnostics and Imaging Centers, Academic and Research Institutes, and Others.
The hospitals & clinics category held the largest share in the market over the forecast period because there are more people with breast cancer globally. Moreover, hospitals frequently do biopsy since they have qualified medical professionals, making them a popular location for the procedure. In addition, a tiny amount of tissue is typically removed during a breast biopsy by the doctor using a needle or through surgery. The majority of surgical biopsies are also performed in hospitals and clinics, which increases the demand for breast biopsies.
A large portion of the market was held by academic and research institutions. Academic and research institutes have made significant contributions to the invention and improvement of biopsy tools. These organizations take part in a range of breast biopsy-related activities, including study, experimentation, testing, and instruction. In addition to conducting applied research to create new breast biopsy equipment or improve those that already exist, they may conduct basic research to comprehend the biology at the root of cancer and other diseases.
Breast Biopsy Regional Insights
Based on region, the Breast Biopsy Market has been segmented into North America, Europe, Asia-Pacific, India and Rest of the World.
Throughout the forecast period, the North American region is expected to dominate the Breast biopsy market. The region's economic growth is significantly influenced by rising financing for biomedical research, notably molecular imaging, from governmental and non-governmental groups. For instance, SNMMI announced on October 3, 2022, a grant of USD 100,000 for nuclear medicine imaging research and development to find a cure for lobular mammary neoplasia. A boost in research efforts in this area is made possible by increased financing, which opens up several opportunities for creative ideas that result in the introduction of new products. An important element influencing the growth of the market for mammary imaging-based Breast Biopsy in this region is the rising number of market participants investing in them. The number of molecular imaging-based biomedical and biotechnological products is anticipated to develop quickly due to the rising number of startups in this region, which is anticipated to boost market revenue growth over the forecast period.
Europe's Breast biopsy market has grown significantly in recent years. The region's market value is growing as a result of the rising cancer prevalence. For instance, in Europe, the BENELUX region has the highest tendency for breast cancer. The three countries with the greatest incidence of breast cancer in 2020 were Belgium, the Netherlands, and Luxembourg, according to World Cancer Research Fund International (WCRF). Modern breast biopsy tools are responsible for early breast cancer detection. The need for cutting-edge biopsy equipment is anticipated to expand as the region's incidence of breast and other cancers rise.
One of the main factors influencing the growth of the market for vacuum assisted biopsies in this region is the high-income population's interest in using them. For instance, the International Monetary Fund (IMF) estimates that the GDP per person in the United Kingdom, France, Germany, Norway, and Sweden will be 51.29 USD, 42.65 USD, 49.43 USD, 88.75 USD, and 60.47 USD, respectively, in 2023.
The market for Breast biopsy is anticipated to be dominated by Asia-Pacific. Growing demand for early-stage mammary neoplasia diagnosis, brought on by an increase in the number of cancer patients in the area, is a key driver of market revenue growth in this area. Breast cancer accounted for 10.6% of all fatalities in India in 2020 and 13.5% of all cancer diagnoses, according to the National Center for Biotechnology Information. The need for new breast biopsy machines and the installation of sophisticated computer-aided digital devices in the area is being driven by the rising number of cancer patients in the region.
A significant factor influencing the segment's revenue growth is the rise in governmental programmes and awareness campaigns to assist breast cancer screening and detection. For instance, the state government of Goa, India, introduced the Swasth Mahila Swasth Goa Initiative on October 26th, 2021. A bike rally campaign was planned for March 12, 2021, to raise awareness of breast cancer treatments. Such public service announcements and free medical checkup clinics result in increased demand for breast biopsy instruments.
Furthermore, over the projection period, it is anticipated that the rest of the world would witness significant growth in the Breast biopsy market. The main driving forces behind the market's expansion are the rapid economic development that, among other significant factors, raises living standards and increases public awareness of healthcare facilities, high disposable income levels brought on by an increase in employment opportunities, as well as an increase in medical tourism initiatives by governments around the world. The region's capacity to expand its overall industry has been made easier by advancements in technology and medical facilities. Because of improved knowledge of breast lumps that may be felt, early discovery, and self-examination, the market for breast biopsies has grown.
Figure 3: BREAST BIOPSY MARKET BY REGION 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Breast Biopsy Key Market Players & Competitive Insights
Many global, regional, and local vendors characterize the breast biopsy market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality polyamide products to survive and succeed in an intensely competitive market.
The market vendors’ growth depends on market conditions, government support, and industry development. Thus, the vendors should focus on expanding geographically and improving services. Leica Biosystems, C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Becton, Dickinson and Company, Devicor Medical Products Inc., Hologic Inc., Medtronic PLC, Cook Medical Incorporated, Planmed OY, and others are the major companies in the market which compete in terms of availability, quality, price, and technology. They primarily focus on the development of breast biopsy products. Although international players dominate the market, regional and foreign players with small market shares also have a presence.
The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario, combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time to launch new products of breast biopsy and increase the global market share.
Key Companies in the Breast Biopsy Market include
- Leica Biosystems (Germany)
- R. Bard, Inc. (US)
- NuVue Therapeutics (US)
- Argon Medical Devices, Inc. (US)
- Becton, Dickinson and Company (US)
- Devicor Medical Products, Inc. (US)
- Hologic Inc. (US)
- Medtronic PLC (Ireland)
- Cook Medical Incorporated (US)
- Planmed Oy (Finland)
Breast Biopsy Industry Developments
February 2023: The NovaSure V5 global endometrial ablation (GEA) device has been approved in Canada and Europe, according to Hologic Inc. This novel version has improved features that are intended to address a variety of cervical and uterine anatomies. It expands on NovaSure's stellar track record, which includes 3 million people who have benefited from the technology.
November 2022: Government representatives from Mexico and Baja California joined BD (Becton, Dickinson and Company), a major global provider of medical technology, to officially open a new $38.6 million manufacturing facility in Tijuana that will create tools and innovations that enhance medication safety in healthcare settings.
August 2022: The company's first twin stage core biopsy tool, the Mammotome DualCore biopsy system, was introduced by Mammotome. In addition to the Mammotome Elite Tetherless Vacuum-Assisted Biopsy Device (tetherless VABB) and the Mammotome Revolve Dual Vacuum-Assisted Breast Biopsy System, this new core biopsy device offers another choice in the Mammotome ultrasound-guided breast biopsy portfolio (tethered VABB).
Breast Biopsy Market Segmentation
Breast Biopsy Product Type Outlook
- Biopsy Needles
- Biopsy Tables
- Biopsy Wires
- Guidance Systems
- Others
Breast Biopsy Technique Outlook
- Fine Needle Aspiration Biopsy
- Core Needle Biopsy
-
- Stereotactic Core Needle Biopsy
- Vacuum-Assisted Biopsies
- Ultrasound-Guided Core Biopsy
- Freehand Needle Biopsy
- Biopsy Markers
- MRI-Guided Core Needle Biopsy
- Surgical Biopsy
-
- Incisional Biopsy
- Excisional Biopsy
- Wire Localization
- Sentinel Node Biopsy
Breast Biopsy Guidance Technique Outlook
- Ultrasound-Guided Biopsy
- Mammography Guided Magnetic Resonance
- CT Guided Biopsy
- Other Image-Guided Breast Biopsy (Pet and Thermography)
Breast Biopsy End-users Outlook
- Hospitals and Clinics
- Diagnostic and Imaging Centers
- Academic and Research Institutes
Breast Biopsy Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East and Africa
- Africa
- Latin America
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
USD 0.71 billion
|
|
Market Size 2024
|
USD 0.76 billion
|
|
Market Size 2032
|
USD 1.36 billion
|
|
Compound Annual Growth Rate (CAGR)
|
7.4% (2024-2032)
|
|
Base Year
|
2023
|
|
Forecast Period
|
2024-2032
|
|
Historical Data
|
2019 to 2022
|
|
Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends.
|
|
Segments Covered
|
Product Type, Technique, Guidance Technique, End-user, and Region
|
|
Key Companies Profiled
|
Leica Biosystems (Germany), C.R. Bard, Inc. (US), NuVue Therapeutics (US), Argon Medical Devices, Inc. (US), Becton, Dickinson and Company (US), Devicor Medical Products, Inc. (US), Hologic Inc. (US), Medtronic PLC (Ireland), Cook Medical Incorporated (US), Planmed Oy (Finland)
|
|
Key Market Opportunities
|
·      Rise in early-stage breast cancer detection programmes.
|
|
Key Market Dynamics
|
·      Increase in prevalence of breast cancer
·      Rising healthcare expenditure
|
Frequently Asked Questions (FAQ) :
The Breast Biopsy Market is anticipated to reach 1.36 billion during the forecast period of 2024-2032.
The Breast Biopsy Market is expected to grow at a 7.4% CAGR during the forecast period from 2024 to 2032.
The North America region is estimated to hold the largest market share in the Breast Biopsy Market.
The key players include Leica Biosystems (Germany), C.R. Bard, Inc. (US), NuVue Therapeutics (US), Argon Medical Devices, Inc. (US), Becton, Dickinson and Company (US), Devicor Medical Products, Inc. (US), Hologic Inc. (US), Medtronic PLC (Ireland), Cook Medical Incorporated (US), Planmed Oy (Finland)
Biopsy Needles segment dominated the market in 2023.
